A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson ’s Disease

DiscussionMultiple daily doses of PF-06669571 were safe and well tolerated with no notable safety concerns. The pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement.Clinicaltrials.gov identifierNCT02565628.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research